Genomic Testing


FoundationOne Heme is a comprehensive genomic profiling (CGP) test combining DNA sequencing of 406 genes and RNA sequencing of 265 genes for patients with hematologic malignancies, sarcomas or solid tumors where RNA sequencing is desired. 
  • Cancer Type
    Hematologic Malignancies, Sarcomas, Solid Tumors
  • Sample Type
    FFPE, Peripheral Whole Blood, Bone Marrow Aspirate
  • Results Expected
    2 weeks*

What is FoundationOne Heme?

FoundationOne Heme is a laboratory developed CGP test combining DNA sequencing of 406 genes and RNA sequencing of 265 genes for patients with hematologic malignancies, sarcomas or solid tumors where RNA sequencing is desired. FoundationOne Heme detects known, novel and complex fusion events as well as other common genomic alterations (substitutions, indels, and copy number variations). The test can be used by physicians to identify targeted therapy options, detect alterations in prognostic genes, and sub-classify sarcoma diagnoses.


FoundationOne Heme

  • >400

    DNA-sequenced genes

  • >30

    select introns profiled

  • >250

    RNA-sequenced genes

  1. A single test that detects the four main classes of genomic alterations for hematologic cancers, sarcomas, and solid tumors where RNA sequencing is desired
  2. Uses both DNA and RNA sequencing for sensitive detection of translocations and fusions
  3. Reports tumor mutational burden (TMB) and microsatellite instability (MSI), which may inform clinical decision-making and clinical trial enrollment


FoundationOne Heme has been validated to detect the four main classes of genomic alterations.

Validation Study in Blood

Published Clinical Study

Patient-derived xenotransplants (PDX) can recapitulate the genetic driver landscape of acute leukemias

These data emphasize the importance of genomic profiling of PDX and patient samples to ensure concordance before performing mechanistic or therapeutic studies.

View the Published Paper

Published Clinical Study

Antitumor response of VEGFR2- and VEGFR3-amplified angiosarcoma to pazopanib

This exceptional response to pazopanib treatment suggests that a subset of patients with angiosarcoma with genomic alterations in vascular signaling genes may respond well to pazopanib.

View the Published Paper

Explore a selection of the 300+ articles we've published since our founding.

View all reports and validation

Order FoundationOne Heme

We provide physicians with several options for ordering FoundationOne Heme for patients including online, email, and fax. Physicians must first complete a test requisition form to start the process and can expect results within two weeks from the time a specimen is received.

A doctor looking at the camera


FoundationOne Heme can only be ordered by your doctor. Talk with your doctor about whether FoundationOne Heme testing is right for you. Download our financial assistance form or apply online and speak with your healthcare provider today.

Apply Now

Questions? We’re here to help.

Call Foundation Medicine Client Services at (888) 988-3639 between 8:00 am ET and 8:00 pm ET, Monday through Friday. You can also send us an email and a representative will respond during regular business hours.

Contact Us

We have even more to offer.

Learn more about our other tests, FoundationOne®Liquid, FoundationOne®CDx, or explore insights and trials or partnerships.

* Typical turnaround time from receipt of specimen is two weeks